Moxifloxacin: In uncomplicated skin and skin structure infections

Drugs

Volumn 62, Issue 6, 2002, Pages 967-973

  Muijsers, Richard B R ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CEFALEXIN; IRON; ITRACONAZOLE; MOXIFLOXACIN; ORAL CONTRACEPTIVE AGENT; PROBENECID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANITIDINE; THEOPHYLLINE; WARFARIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MULTICENTER STUDY; PHOTOSENSITIVITY DISORDER; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

BACTERIA (MICROORGANISMS); STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 0036234190     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262060-00008     Document Type: Review

References (39)

1. Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections
2. Fluoroquinolone treatment of skin and skin structure infections
3. Combating bacterial resistance in skin and skin-structure infection: Importance of β-lactamase inhibition
4. In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates
5. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains
6. Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin
7. Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests
8. In vitro activity of moxifloxacin, a new 8-methoxyquinolone, against Gram-positive bacteria
9. Bactericidal properties of moxifloxacin and post-antibiotic effect
10. Pronounced postantibiotic effect of quinupristin-dalfopristin in static cultures of Staphylococcus aureus: An effect not seen with other antibiotics
11. Pharmacodynamics of fluoroquinolones
12. Pharmacodynamics of moxifloxacin and levofloxacin against Staphylococcus aureus and Staphylococcus epidermidis in an in vitro pharmacodynamic model
13. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus
14. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus
15. The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus
16. Penetration of moxifloxacin into peripheral compartments in humans
17. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration
18. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
19. Effect of food on the pharmacokinetics of a single oral dose of moxifloxacin 400mg in healthy male volunteers
20. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers
21. Profile of moxifloxacin drug interactions
22. Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction
23. 2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers
24. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxy-fluoroquinolone, in healthy volunteers
25. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans
26. Effect of calcium supplements on the oral bioavailability of moxifloxacin in healthy male volunteers
27. Lack of pharmacokinetic interaction between moxifloxacin, a novel 8-methoxyfluoroquinolone, and theophylline
28. Absence of drug interaction between oral moxifloxacin and intramuscular morphine sulfate in healthy volunteers
29. Effect of probenecid on the kinetics of a single oral 400mg dose of moxifloxacin in healthy male volunteers
30. Efficacy and safety of moxifloxacin (MXF) vs cephalexin in the treatment of mild to moderate uncomplicated skin and skin structure infections (USSSI)
31. Moxifloxacin versus cephalexin in the treatment of uncomplicated skin infections
32. Efficacy and safety of moxifloxacin (MXF) vs cephalexin (with or without metronidazole) in the treatment of mild to moderate uncomplicated skin and skin structure infections (uSSI)
33. Moxifloxacin: A review of its safety profile based on worldwide clinical trials